GeoVax Labs, Inc. Strengthens Scientific Staff and Expertise
August 29, 2018 at 02:00 pm
Share
GeoVax Labs, Inc. announced the strengthening of its scientific team through the addition of two PhD-level scientists. Mary Hauser, PhD, recently joined GeoVax as Scientist II and will contribute to the analysis of immune responses across all of the Company’s infectious disease vaccine programs, as well as help with the development of its oncology program. Mugdha Vasireddi, PhD, recently accepted an offer to join GeoVax as Immunologist beginning in early September and will likewise play an integral role in developing the Company’s various vaccine and oncology development programs. Dr. Vasireddi earned her PhD in Viral Immunology from Georgia State University, where she most recently served as a Research Scientist in the Department of Biology and as a Licensed Clinical Laboratory Director of the National B Virus Resource Center.
GeoVax Labs, Inc. is a clinical-stage biotechnology company developing human vaccines and immunotherapies against infectious diseases and solid tumor cancers using proprietary platforms. Its product pipeline includes ongoing human clinical trials for a Covid-19 vaccine and a gene-directed therapy against advanced head and neck cancers. Its additional research and development programs include preventive vaccines against Mpox and smallpox, hemorrhagic fever viruses (Ebola Zaire, Ebola Sudan and Marburg), Zika virus and malaria, as well as immunotherapies for multiple solid tumors. The Companyâs portfolio of wholly owned, co-owned, and in-licensed intellectual property, stands at over 155 granted or pending patent applications spread over 24 patent families. Its product candidate includes GEO-CM04S1, GEO-CM02, Gedeptin, MVA-VLP-MUC1, GEO-ZM02 and others. Its lead infectious disease candidate is GEO-CM04S1, a COVID-19 vaccine targeting high-risk immunocompromised patient populations.
GEOVAX LABS, INC. 
